Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
EyePoint Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
EyePoint Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 2.2% bzw. 42.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -68.9% betragen.
Wichtige Informationen
2.2%
Wachstumsrate der Gewinne
7.1%
EPS-Wachstumsrate
Pharmaceuticals Gewinnwachstum | 23.9% |
Wachstumsrate der Einnahmen | 42.3% |
Zukünftige Eigenkapitalrendite | -68.9% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 14 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 10 | -201 | -122 | -189 | 7 |
12/31/2025 | 12 | -188 | -133 | -151 | 9 |
12/31/2024 | 41 | -128 | -137 | -115 | 7 |
3/31/2024 | 50 | -79 | -17 | -12 | N/A |
12/31/2023 | 46 | -71 | -2 | 2 | N/A |
9/30/2023 | 43 | -100 | 9 | 12 | N/A |
6/30/2023 | 37 | -106 | 12 | 14 | N/A |
3/31/2023 | 40 | -102 | -64 | -62 | N/A |
12/31/2022 | 41 | -102 | -67 | -65 | N/A |
9/30/2022 | 42 | -78 | -71 | -69 | N/A |
6/30/2022 | 41 | -77 | -64 | -64 | N/A |
3/31/2022 | 39 | -67 | -55 | -55 | N/A |
12/31/2021 | 37 | -58 | -50 | -50 | N/A |
9/30/2021 | 33 | -54 | -28 | -28 | N/A |
6/30/2021 | 39 | -42 | -19 | -19 | N/A |
3/31/2021 | 34 | -44 | -14 | -13 | N/A |
12/31/2020 | 34 | -45 | -15 | -14 | N/A |
9/30/2020 | 36 | -40 | -32 | -32 | N/A |
6/30/2020 | 23 | -52 | -48 | -48 | N/A |
3/31/2020 | 26 | -51 | -60 | -60 | N/A |
12/31/2019 | 20 | -57 | -57 | -57 | N/A |
9/30/2019 | 14 | -58 | -56 | -56 | N/A |
6/30/2019 | 12 | -75 | -53 | -53 | N/A |
3/31/2019 | 6 | -98 | -42 | -42 | N/A |
12/31/2018 | 5 | -86 | -34 | -33 | N/A |
9/30/2018 | 3 | -80 | -28 | -28 | N/A |
6/30/2018 | 3 | -53 | -22 | -22 | N/A |
3/31/2018 | 3 | -25 | -20 | -20 | N/A |
12/31/2017 | 3 | -23 | N/A | -20 | N/A |
9/30/2017 | 8 | -17 | N/A | -20 | N/A |
6/30/2017 | 8 | -18 | N/A | -20 | N/A |
3/31/2017 | 7 | -19 | N/A | -20 | N/A |
12/31/2016 | 7 | -19 | N/A | -20 | N/A |
9/30/2016 | 1 | -24 | N/A | -18 | N/A |
6/30/2016 | 2 | -22 | N/A | -16 | N/A |
3/31/2016 | 2 | -20 | N/A | -15 | N/A |
12/31/2015 | 2 | -20 | N/A | -15 | N/A |
9/30/2015 | 2 | -19 | N/A | 10 | N/A |
6/30/2015 | 27 | 6 | N/A | 10 | N/A |
3/31/2015 | 26 | 8 | N/A | 11 | N/A |
12/31/2014 | 28 | 10 | N/A | 13 | N/A |
9/30/2014 | 28 | 11 | N/A | -11 | N/A |
6/30/2014 | 3 | -13 | N/A | -11 | N/A |
3/31/2014 | 4 | -13 | N/A | -11 | N/A |
12/31/2013 | 2 | -14 | N/A | -11 | N/A |
9/30/2013 | 2 | -13 | N/A | -11 | N/A |
6/30/2013 | 2 | -12 | N/A | -9 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: EYPTDie Einnahmen des Unternehmens (42.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).
Hohe Wachstumseinnahmen: EYPTDie Einnahmen des Unternehmens (42.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EYPT wird voraussichtlich in 3 Jahren unrentabel sein.